• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SeaStar Medical Holding Corporation

    4/22/25 4:05:41 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care
    Get the next $ICU alert in real time by email
    S-8 1 2025_s-8_2022_omnibus_pl.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on April 22, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

    SeaStar Medical Holding Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    001-39927

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

    3513 Brighton Blvd., Suite 410

    Denver, CO

    80216

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Amended and Restated SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan

    (Full title of the plan)

     

    Eric Schlorff
    Chief Executive Officer
    3513 Brighton Blvd.

    Suite 410

    Denver, CO 80216

    (Name and address of agent for service)



    (844) 427-8100

    (Telephone number, including area code, of agent for service)

    With copies of all notices, orders, and communications to:

     

    Joshua Erekson

    Daniel Lyman

    Dorsey & Whitney LLP

    111 South Main Street, Suite 2100

    Salt Lake City, UT 84111

    (801) 933-7360

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”), relating to the SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan (as amended, the “Incentive Plan”), is being filed pursuant to General Instruction E to Form S-8, for the purpose of registering: (i) an aggregate of 260,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”) (after giving effect to the reverse stock split referenced below), of SeaStar Medical Holding Corporation (the “Registrant”), reserved for issuance pursuant to an amendment to the Incentive Plan, which was approved by shareholders on June 4, 2024, (ii) an aggregate of 212,456 Shares reserved for issuance pursuant to the evergreen provision of the Incentive Plan, under which the share reserve is automatically increased annually in accordance with the terms of the Incentive Plan and (iii) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), any additional shares of Common Stock that become issuable under the Incentive Plan by reason of any stock dividend, stock split, or other similar transaction.

     

    The Shares are securities of the same class and relate to the same employee benefit plan as the 50,800 shares of Common Stock (after giving effect to the reverse stock split referenced below) registered for issuance pursuant to the Registration Statement on Form S-8, File No. 333-270070, filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on February 27, 2023 and the 47,200 shares of Common Stock (after giving effect to the reverse split referenced below) registered for issuance pursuant to the Registration Statement on Form S-8, File No. 333-276978, filed by the Registrant with the SEC on February 9, 2024 (collectively, the “Prior Registration Statements”). This Registration Statement is filed in accordance with General Instruction E to Form S-8. Accordingly, pursuant to General Instruction E, the Registrant hereby incorporates by reference herein the contents of the Prior Registration Statements and hereby deems such contents to be a part hereof, except as otherwise updated or modified by this Registration Statement.

     

    All share amounts referenced above and otherwise in this Registration Statement give effect to a 1-for-25 reverse stock split of the Common Stock, which was effected on June 7, 2024.

     

    PART II.

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the SEC pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference into this Registration Statement:

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025;

     

     

    (b)

    The Registrant’s Current Reports on Form 8-K filed with the SEC on January 13, 2025 (except for Item 7.01 and any exhibits furnished under Item 7.01), January 31, 2025, February 3, 2025 (except for Item 7.01 and any exhibits furnished under Item 7.01), March 13, 2025, March 21, 2025; and March 28, 2025; and

     

     

    (c)

    The description of the Registrant’s Common Stock set forth in the Registrant’s registration statement on Form 8-A/A filed with the SEC on October 31, 2022, as updated by Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025, and any amendment or report filed with the SEC for the purposes of updating such description.

     

    All other reports and other documents subsequently filed with the SEC by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of Exchange Act prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold (other than those furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or other information deemed to have been “furnished” rather than “filed” in accordance with the SEC’s rules), shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports and documents.

     

     


     

    Any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such prior statement. Any statement contained in this Registration Statement shall be deemed to be modified or superseded to the extent that a statement contained in a subsequently filed document that is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    A list of exhibits filed herewith is contained in the Exhibit Index that immediately precedes such exhibits and is incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit
    No.

    Document

    4.1

    Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation, filed with the Secretary of State of Delaware on October 28, 2022 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 4, 2022).

    4.2

    Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 20, 2023).

    4.3

    Second Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 7, 2024).

     

     

    4.4

    Third Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.4 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 27, 2025).

     

     

    4.5

    Second Amended and Restated Bylaws of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 18, 2024).

     

     

    5.1*

    Opinion of Dorsey & Whitney LLP.

    23.1*

    Consent of WithumSmith+Brown, PC independent registered public accounting firm.

    23.2*

    Consent of Dorsey & Whitney LLP (included in Exhibit 5.1 hereto).

    24.1*

    Power of Attorney (included in the signature page to this Registration Statement).

    99.1*+

    Amended and Restated SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan.

    107*

    Filing Fee Table.

    * Filed herewith

    + Denotes compensatory plan or arrangement

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado on this 22nd day of April, 2025.

     

    SeaStar Medical Holding Corporation

    By:

    /s/ Eric Schlorff

    Name:

    Eric Schlorff

    Title:

    Chief Executive Officer

     

    POWER OF ATTORNEY

    Each of the undersigned, whose signature appears below, hereby constitutes and appoints Eric Schlorff as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments to this registration statement and to file the same with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing necessary or appropriate to be done with respect to this registration statement or any amendments hereto in the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue thereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities indicated below on April 22, 2025.

    Name

    Title

    Date

    /s/ Eric Schlorff

    Chief Executive Officer and Director

    (Principal Executive Officer)

    April 22, 2025

    Eric Schlorff

    /s/ David Green

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    April 22, 2025

    David Green

    /s/ Rick Barnett

    Chairman of the Board of Directors

    April 22, 2025

    Rick Barnett

    /s/ Kenneth Van Heel

    Director

    April 22, 2025

    Kenneth Van Heel

    /s/ Jennifer A. Baird

    Director

    April 22, 2025

    Jennifer A. Baird

    /s/ John Neuman

    Director

    April 22, 2025

    John Neuman

    /s/ Bernadette N. Vincent

    Director

    April 22, 2025

    Bernadette N. Vincent

     

     


    Get the next $ICU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

      DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by the trial's independent Data Safety Monitoring Review Board (DSMB). SeaStar Medical anticipates the DSMB will report its findings to the company in the third quarter of 2025. The NEUTRALIZE-AKI trial is evaluating the SCD therapy as a treatment for adult patients with Acute Kidney In

      5/13/25 8:05:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

      DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

      5/7/25 10:00:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

      DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show. The event will be broadcast live and can be viewed at https://youtube.com/live/ki1hFktn_2Y?feature=share. An archived recording of the presentation will be available on the investor relations section of the Sea Star Medical's website on the Events and Presentations pa

      4/30/25 8:05:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SeaStar Medical Holding Corporation

      SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

      11/14/24 5:35:52 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Chung Kevin

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      4/3/25 7:33:39 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Green David A

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      4/3/25 7:33:07 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      2/27/25 3:51:55 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      2/27/25 3:51:55 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Chung Kevin bought $8,458 worth of shares (4,250 units at $1.99), increasing direct ownership by 45% to 13,685 units (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      11/19/24 5:18:50 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Chung Kevin bought $4,258 worth of shares (1,000 units at $4.26), increasing direct ownership by 12% to 9,435 units (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      10/1/24 4:47:46 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Financials

    Live finance-specific insights

    See more
    • SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

      DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

      5/7/25 10:00:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. "Our significant accomplishment in 2024 position us well for a transformational year in 2025," said Eric Schlorff, SeaStar Medical CEO. "Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinic

      3/27/25 4:05:00 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

      DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT  Webcast:The live webcast and replay can be found here.  Conference ID:2078693  Dial-in numbers:1 (800) 715-9871 within the U.S.   1 (646) 307-1963 from outside

      3/24/25 5:30:00 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    SEC Filings

    See more
    • SEC Form DEF 14A filed by SeaStar Medical Holding Corporation

      DEF 14A - SeaStar Medical Holding Corp (0001831868) (Filer)

      5/7/25 9:05:41 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by SeaStar Medical Holding Corporation

      DEFA14A - SeaStar Medical Holding Corp (0001831868) (Filer)

      5/6/25 5:26:23 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by SeaStar Medical Holding Corporation

      EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)

      4/30/25 12:15:20 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care